Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

by · The Cerbat Gem

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Free Report) was the target of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 58,200 shares, a decline of 25.9% from the February 13th total of 78,500 shares. Based on an average trading volume of 22,900 shares, the days-to-cover ratio is currently 2.5 days. Currently, 0.5% of the shares of the company are sold short.

Indaptus Therapeutics Price Performance

Shares of INDP stock traded up $0.01 on Monday, hitting $0.81. 86,573 shares of the stock traded hands, compared to its average volume of 45,466. The company’s fifty day moving average is $0.85 and its 200 day moving average is $1.07. Indaptus Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.10. The company has a market capitalization of $11.47 million, a PE ratio of -0.48 and a beta of 1.60.

Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. As a group, equities research analysts expect that Indaptus Therapeutics will post -1.79 EPS for the current year.

Indaptus Therapeutics Company Profile

(Get Free Report)

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.

Further Reading